Our study on immune profiling of a solid organ transplant recipient with SARS-CoV-2 reinfection is now published.

Congrats to lead authors @sneakyvirus1 @AndersonBrito_ Paul Trubin @peowenlu and senior authors Marwan Azar & @BenIsraelow 👏🏼 👏🏼 (1/)

academic.oup.com/jid/advance-ar…
For description of this study, please see my thread from when we first posted the paper in @medrxivpreprint in March 👇🏽 One of the deepest immune profiling that captures reinfection in a longitudinal manner. (2/)

In a nutshell, this transplant patient had, prior to reinfection;

• Huge levels of circulating innate and adaptive cytokines (chronic inflammation)
• Very few naive lymphocytes & dominant exhausted T cells
• Elicited poor and transient neutralizing Ab responses
(3/)
We are delighted to have this study published in the Journal of Infectious Diseases @IDSAInfo!

Kudos to @BenIsraelow @YaleIDFellows for bringing this over the finish line 💪🏼

And thank you @Primary_Immune for encouraging me to post this thread 🙏🏼

(end)

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Prof. Akiko Iwasaki

Prof. Akiko Iwasaki Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @VirusesImmunity

11 Oct
In our study published today, we show;

1) mRNA vaccines (2 shots) induce robust antibodies & T cells to SARS-CoV-2
2) certain mutations in VOC ⬆️ Ab escape
3) prior infection + 2 mRNA shots produce very high neutralizing Ab against most VOC 🦠(1/)

nature.com/articles/s4158…
If the link above does not work, here is a full text access of our paper. (2/)

rdcu.be/czi6G
For an explanatory thread on this study please see👇🏽
(3/)

Read 6 tweets
2 Oct
An important new study looks at how COVID vaccines impacts symptoms in #LongCovid patients. @thitran3’s team used data from ComPaRe long COVID cohort to emulate a target trial (1:1 matched vax:unvax) measuring outcome at 120 days after baseline. (1/)

papers.ssrn.com/sol3/papers.cf…
The study found that the rate of complete remission from long COVID symptoms doubled in vaccinated patients compared to unvaccinated long COVID patients. Wow, vaccines appear to be helping long haulers with recovery 👏🏼 (2/)
In addition, disease impact of long covid on patients’ lives were significantly reduced (symptoms improved) in vax group (long COVID IT score of 24.3) compared to unvax group (IT score of 27.6). (3/)
Read 8 tweets
6 Sep
I am very proud of @marioph13, @peowenlu and @ValterVSM for participating in #scicomm. They explained viral plaque assay, flow cytometry and ELISA to news reporter from WAPA TV 🇵🇷 via @dacolon

Me: Cloro no, vacuna sí! (1/)

wapa.tv/programas/cuar…
Here is @Marioph13 explaining viral plaque assay en español 🤩 (too bad his excellent explanation did not make it into the video clip) (2/)
Here, @ValterVSM explains ELISA, how it can detect levels of antibodies in a person, and what antibody levels mean for protection against SARS-CoV-2 VOCs 💪🏼 (3/)
Read 6 tweets
2 Sep
Excited to share our work by @BenIsraelow et al published today. We asked what are the roles of antibodies vs. T cells in controlling primary infection, reinfection, and vaccine-mediated protection? (1/n)

science.org/doi/10.1126/sc…
First, we asked if B cells are needed to control primary infection. We used muMT mice (devoid of B cells) transduced with AAV-hACE2. These mice had only a slight delay in viral clearance. Thus B cells are not necessary for controlling primary SARS-CoV-2 infection. (2/n)
However, in mice that have neither T cells nor B cells (RAG-/-), SARS-CoV-2 persisted with no sign of clearance. Thus, innate immunity is insufficient, and adaptive immunity is required to control primary infection. (3/n)
Read 15 tweets
10 Aug
In this new Neuroview in @NeuroCellPress, I discuss "How COVID-19 has transformed my science”. Recounting my personal journey of how I responded to the pandemic, and how the pandemic has transformed the way I do science. Some lessons learned. (1/n)

cell.com/neuron/fulltex…
Glad to highlight my amazing colleagues who made team science possible. The Yale IMPACT team, Albert Ko, @SaadOmer3 @NathanGrubaugh @ShelFarFar @CharleszYaleMed @EllenFoxman Allison Nelson & many others. @wade_schulz opened my 👀 to the power of data science (2/)
Yale IMPACT team made quite a contribution on our understanding of viral transmission, detection, disease and immunology behind COVID-19. @EricTopol says it best👇🏽 (3/)

Read 11 tweets
19 Jul
How do the various mutations within the SARS-CoV-2 variants impact vaccine-induced immunity? The amazing @carolilucas @VogelsChantal @InciYildirim11 led this study with with help from others to tackle this question - using 18 CoV-2 variants. (1/n)

medrxiv.org/content/10.110…
The study was designed to measure antibody and T cell immunity from people who were previously infected or not infected with SARS-CoV-2, before and after the 1st and 2nd doses of mRNA vaccines. Amazing effort by @InciYildirim11 @SaadOmer3 (2/n)
Antibodies to the ancestral S1 and RBD were induced in both prev. infected and uninfected vaccinees. S/S1/RBD-specific IgG levels in response to vaccination were significantly higher in the previously infected compared to uninfected, as reported by others. (3/n)
Read 17 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!

:(